Cefdrison Injection 1g (Ceftriaxone Sodium Hydrate)

Adult administration

In adults and children over 12 years old, ceftriaxone is administered intravenously or intramuscularly at a dose of 1-2g (potency) once daily. For infections caused by severe or moderately sensitive pathogens, the dose can be increased up to 4g (potency) once daily.

Child administration

In newborns (within 14 days of birth), a dose of 20-50mg (potency) per kg body weight is administered once daily, not exceeding 50mg (potency). For infants and children (from 15 days to 12 years), a dose of 20-

This medication should not be mixed with solutions containing calcium or other drugs. Especially in neonates, contact with calcium can cause precipitation leading to serious side effects, so it must not be administered. Patients who are allergic to this drug or have had hypersensitivity reactions to cephalosporins or penicillin antibiotics should not use it. Caution is needed in patients with allergies to certain local anesthetics like lidocaine, and when administered intravenously, it should not be used with solutions containing lidocaine. The use of this drug is contraindicated in newborns and premature infants who have issues with bilirubin binding. During the use of this drug, various side effects such as allergic reactions, blood abnormalities, gastrointestinal issues, and neurological problems may occur, hence the patient must be closely monitored. If severe allergic reactions or shock symptoms appear, administration must be stopped immediately and appropriate emergency care provided. Regular checking of liver and kidney function during long-term or high-dose administration is important. This medication may interact with other drugs, so caution is especially needed when combined with diuretics or aminoglycoside antibiotics with respect to renal function. Pregnant or nursing women should carefully consider the risks and benefits of this drug and consult a doctor if possible. The safety of this drug in pediatric populations, especially in newborns and premature infants, is not fully established, so caution is advised. In elderly patients, monitoring for physical function decline and bleeding risk is necessary. This drug can affect blood glucose tests or urine sugar tests, so caution is required during testing. Local reactions such as pain, inflammation, and phlebitis may occur at the injection site, so the administration technique and pace must be managed carefully. The prepared solution should be used as soon as possible, and maintaining a proper temperature during storage is crucial.

Serious side effects

Urticaria, severe swelling (edema), tightness in the chest, difficulty breathing, cold sweat, pallor, severe rash with fever, blisters, skin peeling, pain in mucous membranes of mouth/eyes, difficulty breathing or shortness of breath, asthma attacks, respiratory issues accompanied by cough + fever, yellowing of skin or eyes (jaundice), severe lethargy, sudden and severe headache, thunderclap headache, seizures, confusion of consciousness, visual disturbances, paralysis, urination.

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• elevated liver enzymes
• headache
• dizziness
• itching
• hematuria

This medication should be stored in a tightly sealed container to prevent air or moisture ingress, ideally at room temperature between 1 to 30 degrees Celsius. Proper storage helps to maintain the drug's effectiveness for a longer period.

Appearance

A colorless and transparent vial filled with a white to pale yellow crystalline powder.

Package unit

10 vials